+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07748039

Evaluation of Tenecteplase or Reteplase as Bridging Thrombolysis Before Mechanical Thrombectomy in Acute Ischemic Stroke with Large Vessel Occlusion

Led by Yongjun Wang · Updated on 2026-10-22

1440

Participants Needed

5

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the best approach to treat acute ischemic stroke caused by large vessel occlusion LVO, a leading cause of disability. Mechanical thrombectomy MT is the current standard treatment, but the role of intravenous thrombolysis before MT is unclear. This phase 3 randomized trial evaluates different thrombolysis strategies using tenecteplase or reteplase compared with direct MT alone in adults presenting within 4.5 hours of stroke onset with confirmed anterior circulation LVO. Participants will be randomly assigned to one of three groups tenecteplase plus MT, reteplase plus MT, or direct MT without thrombolysis. Tenecteplase is given as a single intravenous bolus dose of 0.25 mgkg, while reteplase is administered as two 18 mg bolus injections separated by 30 minutes. Mechanical thrombectomy is performed according to standard practice. The study aims to determine if bridging thrombolysis improves functional independence at 90 days after treatment, with further comparison between the two thrombolytic agents if superiority is found. Throughout the study, participants will be assessed for functional outcomes, neurological improvement, reperfusion success, quality of life, and safety measures up to 90 days after randomization. Assessments include imaging, clinical evaluations, and monitoring for complications such as bleeding or mortality. The primary outcome is achieving functional independence, defined by a modified Rankin Scale score of 0 to 2 at 90 days. The total study duration extends to the final follow-up at 90 days post-treatment.

CONDITIONS

Brief Title

Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events

Research Team

Y

Yongjun Wang, MD

B

Bowei Zhang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here